NCT01123980View on ClinicalTrials.gov

Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

521

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart 30

Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.

DRUG

metformin

"China: Tablets, 500 mg. Min. 1500 mg/day.~Japan: Tablets, 250 mg. Min 500 mg/day."

DRUG

glimepiride

"China: Tablets, 2 mg. Min. 4 mg/day.~Japan: Tablets, 1 mg. Min. 4 mg/day."

DRUG

insulin glargine

Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.

Trial Locations (34)

100029

Novo Nordisk Investigational Site, Beijing

100101

Novo Nordisk Investigational Site, Beijing

100191

Novo Nordisk Investigational Site, Beijing

100700

Novo Nordisk Investigational Site, Beijing

100853

Novo Nordisk Investigational Site, Beijing

110001

Novo Nordisk Investigational Site, Shenyang

110004

Novo Nordisk Investigational Site, Shenyang

110021

Novo Nordisk Investigational Site, Shenyang

116011

Novo Nordisk Investigational Site, Dalian

150001

Novo Nordisk Investigational Site, Harbin

210012

Novo Nordisk Investigational Site, Nanjing

210029

Novo Nordisk Investigational Site, Nanjing

214023

Novo Nordisk Investigational Site, Wuxi

300052

Novo Nordisk Investigational Site, Tianjin

300070

Novo Nordisk Investigational Site, Tianjin

300211

Novo Nordisk Investigational Site, Tianjin

330006

Novo Nordisk Investigational Site, Nanchang

350025

Novo Nordisk Investigational Site, Fuzhou

400010

Novo Nordisk Investigational Site, Chongqing

450052

Novo Nordisk Investigational Site, Zhengzhou

710061

Novo Nordisk Investigational Site, Xi'an

5008717

Novo Nordisk Investigational Site, Gifu City, Gifu

5300025

Novo Nordisk Investigational Site, Osaka

078 8510

Novo Nordisk Investigational Site, Asahikawa-shi, Hokkaido

103 0002

Novo Nordisk Investigational Site, Chuo-ku, Tokyo

812 8582

Novo Nordisk Investigational Site, Higashiku

862 0976

Novo Nordisk Investigational Site, Kumamoto-shi,Kumamoto

108 0073

Novo Nordisk Investigational Site, Minatoku

545 8586

Novo Nordisk Investigational Site, Osaka-shi, Osaka

321 0293

Novo Nordisk Investigational Site, Shimotsuka-gun

329 0433

Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi

424 0853

Novo Nordisk Investigational Site, Shizuoka

985 0852

Novo Nordisk Investigational Site, Tagajō-shi

235 0045

Novo Nordisk Investigational Site, Yokohama

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY